Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 3 - Studien 21 bis 30 von insgesamt 85
- Rekrutierung läuftA Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
- Rekrutierung läuftA Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies
- Rekrutierung läuftA Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)Molekulare Marker
- Rekrutierung läuftPhase 3, Randomized, Open-Label Study of Belentamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnose Multiple Myeloma who are inelegible for ASCT
- Rekrutierung läuftLenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintance – A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)
- Rekrutierung läuftA randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma
- Rekrutierung läuftGMMG HD9/ DSMM XVIII: A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
- Rekrutierung läuftA Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination withDaratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib asInduction Therapy and Teclistamab in Combination with Daratumumab andLenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
- Rekrutierung läuftNicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikulären Lymphomen inkl. Biomaterial-Sammlung für Patienten mit Marginalzonenlymphom
- Rekrutierung läuftNicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikulären Lymphomen inkl. Biomaterial-Sammlung für Patienten mit Marginalzonenlymphom